Hepatocyte Transplantation as a Life Support Bridge
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00282542|
Recruitment Status : Withdrawn
First Posted : January 26, 2006
Last Update Posted : January 31, 2017
|Condition or disease||Intervention/treatment||Phase|
|Fulminant Liver Failure||Procedure: Hepatocyte Infusion||Not Applicable|
Adult and pediatric patients eligible for liver transplantation who require intensive care unit admission for multisystem organ failure in addition to liver failure, without systemic sepsis, are eligible for liver cell transplantation regardless of race, sex or financial support.
Failure of 3 or more organ systems are the criterion used to select patients with as close to 100% mortality as possible without solid organ transplant.
Hepatocytes, isolated from excess liver tissure from reduced liver transplant procedures or from donor livers not used for transplantation, are prepared by a complex process and then are infused, guided by radiology into the splenic artery or portal vein of the patient. Patients must be on immunosuppression therapy for as long as the hepatocytes are living and beneficial to the patient.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure|
|Study Start Date :||May 2000|
|Study Completion Date :||January 2006|
- Survival to liver transplantation
- Liver Function Normalization
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00282542
|Principal Investigator:||Robert A Fisher, MD, FACS||VCU Health System|